Clinical trials on Psoriasis

Understanding Psoriasis: An Overview

Psoriasis is a chronic, non-contagious skin condition characterized by the rapid buildup of skin cells. This accelerated growth leads to the formation of thick, red patches that are often covered with silvery scales. These patches can cause significant discomfort, including itching, burning, and stinging sensations. Psoriasis is believed to be an autoimmune condition, where the immune system mistakenly attacks healthy skin cells, accelerating their growth cycle. The exact cause of psoriasis remains unknown, but it is thought to be influenced by genetic and environmental factors.

Types and Symptoms

There are several types of psoriasis, each with distinct characteristics:

  • Plaque Psoriasis: The most common form, characterized by raised, inflamed, red lesions covered with a silvery white buildup of dead skin cells.
  • Guttate Psoriasis: Typically triggered by a bacterial infection, this type appears as small, dot-like lesions.
  • Inverse Psoriasis: Shows up as very red lesions in body folds, such as behind the knee, under the arm, or in the groin.
  • Pustular Psoriasis: Characterized by white pustules surrounded by red skin.
  • Erythrodermic Psoriasis: A rare and severe form causing widespread redness, severe itching, and pain.

While there is currently no cure for psoriasis, a variety of treatments exist aimed at managing symptoms and improving the quality of life for those affected. These treatments range from topical creams and ointments to light therapy and systemic medications. Understanding the nature of psoriasis and seeking appropriate medical advice are crucial steps in effectively managing this complex condition.

Prognosis for Psoriasis: Understanding Long-Term Outcomes

Psoriasis is a chronic autoimmune condition characterized by the rapid growth of skin cells, leading to thick, red, scaly patches on the skin. The long-term prospects for those with psoriasis vary, as the disease often follows a fluctuating course with periods of remission and flare-ups. While psoriasis is currently incurable, symptoms can often be managed effectively with ongoing care. The severity of psoriasis can range from mild to severe, and the extent of skin involvement is a key factor in determining the impact on quality of life. Some may experience only minor irritation, while others face more significant physical discomfort and potential social or psychological challenges. The disease does not typically affect life expectancy, and many lead full, active lives. However, it is important to note that psoriasis can be associated with an increased risk of developing other health conditions, such as psoriatic arthritis, which can influence the overall prognosis.

Complications in Psoriasis: Understanding the Impact on Health

Living with psoriasis can lead to more than just skin issues. The condition may increase the risk of developing other health concerns. Joint problems, such as psoriatic arthritis, can arise, causing pain and stiffness that may hinder daily activities. Psoriasis is also linked with a higher chance of cardiovascular problems, which includes heart disease, due to inflammation. Mental health can be affected as well, as the visible nature of psoriasis might lead to feelings of self-consciousness, stress, or even depression. Additionally, there may be a greater likelihood of obesity and type 2 diabetes among individuals with psoriasis. These complications can significantly affect the quality of life, making it essential to be aware of the broader health implications of psoriasis beyond the skin.

Treatment Methods for Psoriasis

For the management of psoriasis, several non-clinical trial alternatives are recommended. Dietary adjustments, such as the incorporation of anti-inflammatory foods like omega-3-rich fish, nuts, and leafy greens, can be beneficial. The reduction of alcohol intake and the avoidance of processed foods may also help. Regular physical activity is encouraged to maintain a healthy weight and reduce flare-ups.

Pharmacotherapy options include topical treatments like corticosteroids, vitamin D analogues, and moisturizers to alleviate symptoms. Systemic medications, available for more severe cases, are taken orally or by injection and include retinoids, methotrexate, and cyclosporine. Biologic drugs, which target specific parts of the immune system, are another advanced option.

Modern technology offers phototherapy, which involves exposing the skin to ultraviolet light under medical supervision. This treatment can help slow skin cell turnover, reducing scaling and inflammation. Laser therapy is a more targeted form of light treatment that can be effective for localized psoriasis patches.

The adoption of these methods can significantly improve the quality of life for individuals living with psoriasis.

  • CT-EU-00054021

    Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    • Brodalumab
  • New antibody treatment for psoriasis and healthy individuals

    This phase I trial, the first of its kind, is designed to assess the safety and impact of a new medication known as CAN10. CAN10 is an antibody, a type of protein within the immune system that aids in disease defense. The medication will be tested on both healthy individuals and individuals with plaque psoriasis, a skin condition. The study is designed to be unbiased, with some participants receiving the actual treatment (CAN10) while others receive a placebo, an inactive substance. This is done to ascertain whether the observed effects are attributed to CAN10 or other variables. CAN10 will be administered once to healthy participants. In the second phase, CAN10 will be administered as repeated subcutaneous doses to individuals with psoriasis to observe its effects over time.

    • CAN10
  • Exploring the efficacy and safety of new drug in Psoriasis Treatment

    This clinical trial is for patients suffering from a skin condition called mild to moderate psoriasis. The aim of the study is to check the effectiveness and safety of a new drug called HRO350. HRO350 is a soft capsule containing oil extracted from herring roe (fish roe). This oil contains natural substances called phospholipids, which are rich in certain fatty acids. These substances have the potential to slow or stop the inflammation that causes psoriasis. Patients in the study will take HRO350 capsules or a placebo (a dummy medicine that contains no active substance) every day for up to a year. They will also have an 8-week follow-up period after completing treatment. Approximately 519 patients will participate in the study. The test will involve regular check-ups, including blood and urine tests, and an assessment of the severity of patients’ psoriasis.

    • HRO350- new potential medication for psoriasis
  • Exploring a new treatment in psoriasis and healthy volunteers: A safety and tolerability study

    A clinical trial is evaluating a new antibody called CAN10 for the treatment of plaque psoriasis, a skin condition characterized by red, scaly patches. The study is designed to determine the safety and tolerability of CAN10 and includes both healthy volunteers and people with mild to moderate symptoms of plaque psoriasis. Participants will be randomly assigned to receive the antibody or placebo injections – either just once (for healthy volunteers) or repeatedly (for patients with psoriasis). The response to these doses, including any side effects, will be monitored for up to 57 days after the last dose. Researchers will also measure how the body processes the antibody by observing the concentration of CAN10 in the blood at various points after the dose to understand how long it remains active in the body. This study is part of the initial steps to establish CAN10’s potential as a new treatment option for people affected by plaque psoriasis.

    • CAN10